NEW YORK (GenomeWeb News) – Exosome Diagnostics today said that Promega will be the exclusive supplier of its Urine Clinical Sample Concentrator Kit, which incorporates Exosome's technology for concentration of urinary exosomes.
The kit is sued for molecular diagnostic applications, and New York-based Exosome said that it will be used to process urine samples for clinical trials in genitourinary disorders, such as prostate cancer. Financial and other terms of the agreement weren't disclosed.
"This agreement is another important milestone in the execution of our molecular diagnostics commercial strategy," Exosome Diagnostics CEO James McCullough said in a statement. "We're pleased to be working with Promega, a manufacturer who has decades of experience in coupling the latest scientific advances in molecular biology with excellent cGMP manufacturing capability."